InvestorsObserver
Sign Up Login

RPHM Reneo Pharmaceuticals Inc

$1.66 $-0.02 (-1.19%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

RPHM Stock Analysis Overview

What this means: Reneo Pharmaceuticals Inc (RPHM) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives RPHM a rank of 7. Our methodology considers analysis of the company's financial situation and how it has traded recently. RPHM rank of 7 means that it ranks below 93% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

RPHM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

RPHM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

RPHM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

RPHM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

RPHM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

RPHM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

RPHM Stock Analysis Overview

What this means: Reneo Pharmaceuticals Inc (RPHM) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives RPHM a rank of 7. Our methodology considers analysis of the company's financial situation and how it has traded recently. RPHM rank of 7 means that it ranks below 93% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full RPHM report

RPHM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

RPHM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

RPHM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

RPHM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

RPHM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

RPHM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Reneo Pharmaceuticals Inc (RPHM) Analyst Forecast

RPHM Price, Volume, Earnings, and Dividend Date

  • Last Price $1.66
  • Previous Close $1.68
  • Change $-0.02
  • Open $1.68
  • Volume 42,564
  • Avg. Volume (100-day) 745,990
  • Market Cap 56,146,957
  • Days Range 1.62 - 1.68
  • 52-week Range 0.98 - 10.98
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 05/09/24
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta -0.678
  • PEG Ratio —

Reneo Pharmaceuticals Inc (RPHM) Company Description

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Reneo Pharmaceuticals Inc (RPHM) Stock Chart

View Interactive RPHM chart

My Watchlists

Top Stocks in Biotechnology